Abundant supply of Remdesivir by the second week of May: Kiran Mazumdar Shaw

Biocon Executive Chairperson Kiran Mazumdar Shaw says scarcity of critical anti-COVID-19 drugs Remdesivir and Itolizumab will end in 4-6 weeks as suppliers like her own company ramp up output that fell when the pandemic was receding. She said market pricing of vaccines is a must for the much-needed acceleration in inoculation.

The second wave of Covid-19 has hit India with ferocity. Desperate pleas for help abound in social media as families struggle for hospital beds, oxygen, and drugs used to treat the virus. Biocon, which manufactures two critical drugs, Remdesivir and Itolizumab, is ramping up manufacturing to meet the sudden surge in demand.